Fierce Pharma Asia—Takeda's narcolepsy trial problem, gene therapy pact; human error in Moderna's COVID vaccine
Takeda halted two trials for a narcolepsy candidate to examine a safety signal. The Japanese pharma also signed a gene therapy pact potentially worth over $1 billion with Selecta Biosciences. Moderna has identified "human error" as the source of contaminations in its halted COVID-19 vaccine doses in Japan. And more.
Source: fiercepharma.com